andecaliximab andecaliximab andecaliximab (inn; development code gs-5745) is an experimental humanized monoclonal antibody designed for the treatment of cancer and inflammatory diseases. andecaliximabmonoclonal antibodytype?sourcechimeric (mouse/human)targetgelatinase bclinical dataother namesgs-5745atc codenoneidentifierscas number1518996-49-0chemspidernoneunii571045eim4keggd11262chemical and physical dataformulac6396h9868n1680o2010s46molar mass143933.81 g·mol−1 this drug was developed by gilead sciences, inc. phase ii and phase iii trials for gastric cancer or gastroesophageal junction adenocarcinoma completed in 2019.